心臟生物標記的全球市場預測（~2030 年）：按產品類型、測試地點、應用、最終用戶和區域進行分析

2023年，全球心臟生物標記市場規模為187億美元，預計預測期內複合年成長率為16.6%，到2030年將達到548億美元。心臟生物標記是由於心臟受傷、損傷或壓力而釋放到血液中的特定分子或蛋白質。

肌鈣蛋白、肌酸激酶 MB (CK-MB) 和 B 型利鈉胜肽(BNP) 等生物標記在診斷上用於指示心臟相關疾病。這些檢測到的數值和濃度有助於診斷心臟病、心臟衰竭和其他心臟疾病，確定治療策略並評估心臟健康狀況。

根據世界衛生組織 (WHO) 的數據，18 歲以上的成年人中有 7700 萬人患有第 2 型糖尿病，其中 2500 萬人患有糖尿病前期。這增加了心血管疾病的風險，並給醫療保健系統帶來了進一步的壓力。

心血管疾病增加

心肌梗塞、心臟衰竭和心肌缺血等心臟相關疾病的全球負擔日益增加，增加了對可靠診斷工具的需求。心臟生物標記是心血管疾病早期發現、診斷和預後的重要指標。它準確評估心臟健康、預測風險和指導治療策略的能力是高效、及時和準確診斷的關鍵，以應對全球範圍內日益增加的心血管疾病發病率。這符合當前的需求。

嚴格規定

嚴格的法規阻礙了心臟生物標記的開發和實用化。嚴格的監管核准流程需要廣泛的臨床檢驗，通常會導致新生物標記的上市時間較長。這些嚴格的指南需要進行全面的研究，以確保檢測心臟病的準確性、敏感性和特異性。遵守這些法規需要在研究、臨床試驗和滿足特定性能標準方面進行大量投資，這增加了成本和時間限制。

越來越重視即時偵測

即時檢測可實現快速、方便的現場診斷，並立即提供結果，而無需將檢體發送到中心實驗室。在心臟治療中，這可以快速檢測肌鈣蛋白等生物標記，從而快速診斷心臟病等心臟疾病。這項轉變將透過加快治療決策（尤其是在緊急情況下）來改善患者照護，也將透過減少週轉時間和提高心臟緊急情況管理的整體效率來支持衛生系統。

替代診斷方法的出現

先進影像技術和即時檢測設備等新技術可能會提供更快、非侵入性且可能更具成本效益的心臟健康評估方法。此類替代技術可能會挑戰傳統生物標記測試的主導地位，並影響市場採用和醫療保健提供者的偏好。

COVID-19 的影響：

COVID-19 大流行將醫療資源轉移到病毒管理上，影響了心臟生物標記測試。非新冠就診次數減少導致心臟評估減少，進而影響了生物標記測試的頻率。此外，一些新冠肺炎患者出現心臟併發症，增加了對生物標記評估的需求。疫情對醫療保健系統造成的壓力已經改變了優先事項，影響了心臟生物標記的利用率，並凸顯了在健康危機期間採取適應性診斷策略的必要性。

肌鈣蛋白部分預計將在預測期內成為最大的部分

肌鈣蛋白片段預計將佔據主導地位，因為它們被廣泛用作診斷心臟相關疾病的敏感和特異性心臟生物標記。肌鈣蛋白，尤其是肌鈣蛋白 I 和肌鈣蛋白 T，在檢測心肌損傷方面表現出良好的敏感性，並且在診斷心臟病發作方面特別有用。由於全世界心血管疾病的盛行率不斷增加，且肌鈣蛋白檢測在日常臨床實踐中的應用越來越多，預計肌鈣蛋白檢測將在預測期內成為心臟生物標記檢測的最大部分。

醫院部門預計在預測期內複合年成長率最高

由於患者在醫院環境中獲得先進醫療服務和診斷設施的機會增加，醫院部門預計將大幅成長。醫院是急診護理的主要中心，心臟生物標記檢測在心臟相關疾病的診斷中發揮著至關重要的作用。心血管疾病盛行率的上升以及醫院環境中及時、準確診斷的需求正在推動這一領域的預期成長。

比最大的地區

由於其成熟的醫療基礎設施、技術進步和高昂的醫療成本，北美預計將主導心臟生物標記市場。該地區強大的研發活動和主要市場參與者的存在幫助其佔領了巨大的市場佔有率。此外，心血管疾病的高盛行率以及人們對先進診斷技術的認知和採用的提高正在推動市場的成長。

複合年成長率最高的地區

由於心血管疾病盛行率的增加、人口老化的加劇以及醫療基礎設施的改善，預計亞太地區心臟生物標記市場將顯著成長。該地區的心臟健康意識不斷增強，推動了對先進診斷工具的需求。此外，政府和醫療機構加強心臟護理的努力也有助於市場擴張。隨著醫療技術的進步，隨著中國和印度等國家擴大採用心臟生物標記物，亞太地區有望見證顯著的市場成長。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

• 公司簡介
  • 其他市場公司的綜合分析（最多 3 家公司）
  • 主要企業SWOT分析（最多3家企業）
• 區域分割
  • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
• 競爭基準化分析
  • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

• 概述
• 相關利益者
• 調查範圍
• 調查方法
  • 資料探勘
  • 資料分析
  • 資料檢驗
  • 研究途徑
• 調查來源
  • 主要調查來源
  • 二次調查來源
  • 先決條件

第3章市場趨勢分析

• 促進因素
• 抑制因素
• 機會
• 威脅
• 產品分析
• 應用分析
• 最終用戶分析
• 新興市場
• 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

• 供應商的議價能力
• 買方議價能力
• 替代品的威脅
• 新進入者的威脅
• 競爭公司之間的敵對關係

第5章全球心臟生物標記市場：依產品類型

• B 型利尿鈉胜肽(BNP)
• 肌酸激酶 - 肌肉/腦 (CK-MB)
• 高敏感性 C 反應蛋白 (hs-CRP)
• 肌紅蛋白
• 肌鈣蛋白
• 其他產品類型

第6章全球心臟生物標記市場：依測試地點

• 即時檢測
• 臨床檢查

第7章全球心臟生物標記市場：依應用分類

• 心肌梗塞
• 鬱血性心臟衰竭
• 急性冠狀動脈症候群
• 其他用途

第8章全球心臟生物標記市場：依最終用戶分類

• 診斷實驗室
• 醫院
• 製藥和生物技術公司
• 研究機構
• 其他最終用戶

第9章全球心臟生物標記市場：按地區

• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙
  • 其他歐洲國家
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 紐西蘭
  • 韓國
  • 其他亞太地區
• 南美洲
  • 阿根廷
  • 巴西
  • 智利
  • 南美洲其他地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 卡達
  • 南非
  • 其他中東和非洲

第10章 主要進展

• 協議、夥伴關係、協作和合資企業
• 收購和合併
• 新產品發布
• 業務擴展
• 其他關鍵策略

第11章 公司簡介

• Abbott Laboratories
• Beckman Coulter
• Becton, Dickinson and Company（BD）
• BG Medicine
• Bio-Rad Laboratories
• Corgenix
• Fujirebio
• Hologic
• Meso Scale Diagnostics（MSD）
• Mindray
• Ortho Clinical Diagnostics
• Pathkind Labs
• Qiagen
• Randox Laboratories
• R-Biopharm AG
• Response Biomedical
• Roche Diagnostics
• Siemens Healthineers
• Singulex Inc
• SRL Diagnostics
• Thermo Fisher Scientific
• Trinity Biotech

According to Stratistics MRC, the Global Cardiac Biomarkers Market is accounted for $18.7 billion in 2023 and is expected to reach $54.8 billion by 2030 growing at a CAGR of 16.6% during the forecast period. Cardiac biomarkers are specific molecules or proteins released into the bloodstream due to heart injury, damage or stress. These biomarkers, such as troponins, creatine kinase-MB (CK-MB), and B-type natriuretic peptide (BNP), are used in diagnostics to indicate heart-related conditions. Their detection and levels aid in diagnosing heart attacks, heart failure or other cardiac diseases, guiding treatment decisions and assessing cardiac health.

According to the World Health Organization (WHO), 77 million adults above 18 years have type 2 diabetes, with 25 million prediabetics. This increases cardiovascular disease risk and puts additional pressure on the health system.

Market Dynamics:

Driver:

Rising cardiovascular diseases

With an increasing global burden of heart-related conditions like heart attacks, heart failure and cardiac ischemia, there's a growing demand for reliable diagnostic tools. Cardiac biomarkers serve as vital indicators, aiding in the early detection, diagnosis, and prognosis of cardiovascular ailments. Their ability to accurately assess heart health, predict risks, and guide treatment strategies aligns with the pressing need for efficient, timely, and precise diagnostics in combating the rising incidence of cardiovascular diseases worldwide.

Restraint:

Stringent regulations

Stringent regulations pose a restraint on cardiac biomarker development and implementation. The rigorous approval processes set by regulatory bodies demand extensive clinical validation, often prolonging the time-to-market for new biomarkers. These stringent guidelines necessitate comprehensive studies to ensure accuracy, sensitivity and specificity in detecting cardiac conditions. Compliance with these regulations involves significant investment in research, clinical trials, and meeting specific performance criteria, leading to increased costs and time constraints.

Opportunity:

Increasing focus on point-of-care testing

Point-of-care tests allow for rapid and convenient on-site diagnostics, offering immediate results without the need for sending samples to a central laboratory. In cardiac care, this facilitates quicker detection of biomarkers like troponins, enabling faster diagnosis of heart conditions such as heart attacks. This shift enhances patient care by expediting treatment decisions, especially in emergency settings and supports healthcare systems by reducing turnaround times and improving overall efficiency in managing cardiac emergencies.

Threat:

Emergence of alternative diagnostic methods

New technologies, such as advanced imaging techniques or point-of-care testing devices, might offer rapid, non-invasive and possibly more cost-effective ways to assess cardiac health. These alternatives could challenge the dominance of traditional biomarker testing, impacting market adoption and preferences among healthcare providers.

Covid-19 Impact:

The COVID-19 pandemic influenced cardiac biomarker testing by diverting healthcare resources towards managing the virus. Reduced non-COVID medical visits led to fewer cardiac evaluations, impacting biomarker testing frequency. Additionally, some COVID patients experienced cardiac complications, increasing the demand for biomarker assessments. The pandemic's strain on healthcare systems altered priorities, affecting cardiac biomarker utilisation and emphasising the need for adaptable diagnostic strategies during health crises.

The troponins segment is expected to be the largest during the forecast period

The troponins segment is projected to dominate due to its widespread use as a highly sensitive and specific cardiac biomarker for diagnosing heart-related conditions. Troponins, especially troponin I and troponin T, exhibit superior sensitivity in detecting myocardial injury, notably for diagnosing heart attacks. The growing prevalence of cardiovascular diseases globally and the increasing adoption of troponin testing in routine clinical practice contribute to its anticipated prominence, making it the largest segment in cardiac biomarker testing during the forecast period.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is poised for substantial growth due to increased patient access to advanced healthcare services and diagnostic facilities in hospital settings. Hospitals serve as primary centres for acute care, where cardiac biomarker testing plays a pivotal role in diagnosing heart-related conditions. Rising incidences of cardiovascular diseases and the need for timely and accurate diagnostics within hospital environments contribute to the segment's anticipated growth.

Region with largest share:

North America's anticipated dominance in the cardiac biomarkers market is attributed to well-established healthcare infrastructure, technological advancements and high healthcare spending. The region's robust research and development activities, along with the presence of key market players, contribute to its significant market share. Additionally, the high prevalence of cardiovascular diseases, coupled with increasing awareness and adoption of advanced diagnostic techniques, drives market growth.

Region with highest CAGR:

The Asia-Pacific region is poised for substantial growth in the cardiac biomarker market due to the increasing prevalence of cardiovascular diseases, a rising ageing population and improving healthcare infrastructure. The region witnesses a growing awareness of cardiac health, driving demand for advanced diagnostic tools. Additionally, initiatives by governments and healthcare organisations to enhance cardiac care contribute to the market's expansion. The increasing adoption of cardiac biomarkers in countries like China and India, along with advancements in healthcare technologies, positions the Asia-Pacific region for significant market growth.

Key players in the market

Some of the key players in Cardiac Biomarkers Market include Abbott Laboratories, Beckman Coulter, Becton, Dickinson and Company (BD), BG Medicine, Bio-Rad Laboratories, Corgenix , Fujirebio, Hologic, Meso Scale Diagnostics (MSD), Mindray, Ortho Clinical Diagnostics, Pathkind Labs, Qiagen, Randox Laboratories, R-Biopharm AG, Response Biomedical, Roche Diagnostics, Siemens Healthineers, Singulex Inc, SRL Diagnostics, Thermo Fisher Scientific and Trinity Biotech.

Key Developments:

In October 2023, Mindray has announced the introduction and global launch of two new high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The additions enhance Mindray's diverse portfolio of cardiac biomarkers for diagnosing and managing cardiovascular diseases (CVDs), according to a written statement issued by the global medical devices and solutions provider.

In January 2023, Pathkind Labs, Roche Diagnostics partner to release cardiac biomarker. This announcement of NTProBNP comes in light of the growing burden of heart failure among T2D patients in India, inciting the need for urgent action. NTProBNP can directly predict adverse outcomes and cardiovascular mortality and can evaluate the overall status of a patient with type 2 diabetes to facilitate the establishment of correct therapy management and follow-up.

In September 2022, SRL Diagnostics launched "Heart Assure," a specialized test that can predict the risk of a cardiac event in an individual. High-sensitivity troponin I is a simple blood test that can precisely predict a cardiac injury by providing a heart health risk score.

Product Types Covered:

• B-Type Natriuretic Peptide (BNP)
• Creatine Kinase-Muscle/Brain (CK-MB)
• High-Sensitivity C-Reactive Protein (hs-CRP)
• Myoglobin
• Troponins
• Other Product Types

Location of Testings Covered:

• Point-of-care Testing
• Laboratory Testing

Applications Covered:

• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome
• Other Applications

End Users Covered:

• Diagnostic Laboratories
• Hospitals
• Pharmaceutical and Biotechnology Companies
• Research Institutions
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Cardiac Biomarkers Market, By Product Type

• 5.1 Introduction
• 5.2 B-Type Natriuretic Peptide (BNP)
• 5.3 Creatine Kinase-Muscle/Brain (CK-MB)
• 5.4 High-Sensitivity C-Reactive Protein (hs-CRP)
• 5.5 Myoglobin
• 5.6 Troponins
• 5.7 Other Product Types

6 Global Cardiac Biomarkers Market, By Location of Testing

• 6.1 Introduction
• 6.2 Point-of-care Testing
• 6.3 Laboratory Testing

7 Global Cardiac Biomarkers Market, By Application

• 7.1 Introduction
• 7.2 Myocardial Infarction
• 7.3 Congestive Heart Failure
• 7.4 Acute Coronary Syndrome
• 7.5 Other Applications

8 Global Cardiac Biomarkers Market, By End User

• 8.1 Introduction
• 8.2 Diagnostic Laboratories
• 8.3 Hospitals
• 8.4 Pharmaceutical and Biotechnology Companies
• 8.5 Research Institutions
• 8.6 Other End Users

9 Global Cardiac Biomarkers Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Abbott Laboratories
• 11.2 Beckman Coulter
• 11.3 Becton, Dickinson and Company (BD)
• 11.4 BG Medicine
• 11.5 Bio-Rad Laboratories
• 11.6 Corgenix
• 11.7 Fujirebio
• 11.8 Hologic
• 11.9 Meso Scale Diagnostics (MSD)
• 11.10 Mindray
• 11.11 Ortho Clinical Diagnostics
• 11.12 Pathkind Labs
• 11.13 Qiagen
• 11.14 Randox Laboratories
• 11.15 R-Biopharm AG
• 11.16 Response Biomedical
• 11.17 Roche Diagnostics
• 11.18 Siemens Healthineers
• 11.19 Singulex Inc
• 11.20 SRL Diagnostics
• 11.21 Thermo Fisher Scientific
• 11.22 Trinity Biotech

List of Tables

• Table 1 Global Cardiac Biomarkers Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Cardiac Biomarkers Market Outlook, By Product Type (2021-2030) ($MN)
• Table 3 Global Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2021-2030) ($MN)
• Table 4 Global Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2021-2030) ($MN)
• Table 5 Global Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2021-2030) ($MN)
• Table 6 Global Cardiac Biomarkers Market Outlook, By Myoglobin (2021-2030) ($MN)
• Table 7 Global Cardiac Biomarkers Market Outlook, By Troponins (2021-2030) ($MN)
• Table 8 Global Cardiac Biomarkers Market Outlook, By Other Product Types (2021-2030) ($MN)
• Table 9 Global Cardiac Biomarkers Market Outlook, By Location of Testing (2021-2030) ($MN)
• Table 10 Global Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2021-2030) ($MN)
• Table 11 Global Cardiac Biomarkers Market Outlook, By Laboratory Testing (2021-2030) ($MN)
• Table 12 Global Cardiac Biomarkers Market Outlook, By Application (2021-2030) ($MN)
• Table 13 Global Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2021-2030) ($MN)
• Table 14 Global Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2021-2030) ($MN)
• Table 15 Global Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2021-2030) ($MN)
• Table 16 Global Cardiac Biomarkers Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 17 Global Cardiac Biomarkers Market Outlook, By End User (2021-2030) ($MN)
• Table 18 Global Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 19 Global Cardiac Biomarkers Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 20 Global Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
• Table 21 Global Cardiac Biomarkers Market Outlook, By Research Institutions (2021-2030) ($MN)
• Table 22 Global Cardiac Biomarkers Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 23 North America Cardiac Biomarkers Market Outlook, By Country (2021-2030) ($MN)
• Table 24 North America Cardiac Biomarkers Market Outlook, By Product Type (2021-2030) ($MN)
• Table 25 North America Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2021-2030) ($MN)
• Table 26 North America Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2021-2030) ($MN)
• Table 27 North America Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2021-2030) ($MN)
• Table 28 North America Cardiac Biomarkers Market Outlook, By Myoglobin (2021-2030) ($MN)
• Table 29 North America Cardiac Biomarkers Market Outlook, By Troponins (2021-2030) ($MN)
• Table 30 North America Cardiac Biomarkers Market Outlook, By Other Product Types (2021-2030) ($MN)
• Table 31 North America Cardiac Biomarkers Market Outlook, By Location of Testing (2021-2030) ($MN)
• Table 32 North America Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2021-2030) ($MN)
• Table 33 North America Cardiac Biomarkers Market Outlook, By Laboratory Testing (2021-2030) ($MN)
• Table 34 North America Cardiac Biomarkers Market Outlook, By Application (2021-2030) ($MN)
• Table 35 North America Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2021-2030) ($MN)
• Table 36 North America Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2021-2030) ($MN)
• Table 37 North America Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2021-2030) ($MN)
• Table 38 North America Cardiac Biomarkers Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 39 North America Cardiac Biomarkers Market Outlook, By End User (2021-2030) ($MN)
• Table 40 North America Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 41 North America Cardiac Biomarkers Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 42 North America Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
• Table 43 North America Cardiac Biomarkers Market Outlook, By Research Institutions (2021-2030) ($MN)
• Table 44 North America Cardiac Biomarkers Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 45 Europe Cardiac Biomarkers Market Outlook, By Country (2021-2030) ($MN)
• Table 46 Europe Cardiac Biomarkers Market Outlook, By Product Type (2021-2030) ($MN)
• Table 47 Europe Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2021-2030) ($MN)
• Table 48 Europe Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2021-2030) ($MN)
• Table 49 Europe Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2021-2030) ($MN)
• Table 50 Europe Cardiac Biomarkers Market Outlook, By Myoglobin (2021-2030) ($MN)
• Table 51 Europe Cardiac Biomarkers Market Outlook, By Troponins (2021-2030) ($MN)
• Table 52 Europe Cardiac Biomarkers Market Outlook, By Other Product Types (2021-2030) ($MN)
• Table 53 Europe Cardiac Biomarkers Market Outlook, By Location of Testing (2021-2030) ($MN)
• Table 54 Europe Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2021-2030) ($MN)
• Table 55 Europe Cardiac Biomarkers Market Outlook, By Laboratory Testing (2021-2030) ($MN)
• Table 56 Europe Cardiac Biomarkers Market Outlook, By Application (2021-2030) ($MN)
• Table 57 Europe Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2021-2030) ($MN)
• Table 58 Europe Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2021-2030) ($MN)
• Table 59 Europe Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2021-2030) ($MN)
• Table 60 Europe Cardiac Biomarkers Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 61 Europe Cardiac Biomarkers Market Outlook, By End User (2021-2030) ($MN)
• Table 62 Europe Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 63 Europe Cardiac Biomarkers Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 64 Europe Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
• Table 65 Europe Cardiac Biomarkers Market Outlook, By Research Institutions (2021-2030) ($MN)
• Table 66 Europe Cardiac Biomarkers Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 67 Asia Pacific Cardiac Biomarkers Market Outlook, By Country (2021-2030) ($MN)
• Table 68 Asia Pacific Cardiac Biomarkers Market Outlook, By Product Type (2021-2030) ($MN)
• Table 69 Asia Pacific Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2021-2030) ($MN)
• Table 70 Asia Pacific Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2021-2030) ($MN)
• Table 71 Asia Pacific Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2021-2030) ($MN)
• Table 72 Asia Pacific Cardiac Biomarkers Market Outlook, By Myoglobin (2021-2030) ($MN)
• Table 73 Asia Pacific Cardiac Biomarkers Market Outlook, By Troponins (2021-2030) ($MN)
• Table 74 Asia Pacific Cardiac Biomarkers Market Outlook, By Other Product Types (2021-2030) ($MN)
• Table 75 Asia Pacific Cardiac Biomarkers Market Outlook, By Location of Testing (2021-2030) ($MN)
• Table 76 Asia Pacific Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2021-2030) ($MN)
• Table 77 Asia Pacific Cardiac Biomarkers Market Outlook, By Laboratory Testing (2021-2030) ($MN)
• Table 78 Asia Pacific Cardiac Biomarkers Market Outlook, By Application (2021-2030) ($MN)
• Table 79 Asia Pacific Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2021-2030) ($MN)
• Table 80 Asia Pacific Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2021-2030) ($MN)
• Table 81 Asia Pacific Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2021-2030) ($MN)
• Table 82 Asia Pacific Cardiac Biomarkers Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 83 Asia Pacific Cardiac Biomarkers Market Outlook, By End User (2021-2030) ($MN)
• Table 84 Asia Pacific Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 85 Asia Pacific Cardiac Biomarkers Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 86 Asia Pacific Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
• Table 87 Asia Pacific Cardiac Biomarkers Market Outlook, By Research Institutions (2021-2030) ($MN)
• Table 88 Asia Pacific Cardiac Biomarkers Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 89 South America Cardiac Biomarkers Market Outlook, By Country (2021-2030) ($MN)
• Table 90 South America Cardiac Biomarkers Market Outlook, By Product Type (2021-2030) ($MN)
• Table 91 South America Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2021-2030) ($MN)
• Table 92 South America Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2021-2030) ($MN)
• Table 93 South America Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2021-2030) ($MN)
• Table 94 South America Cardiac Biomarkers Market Outlook, By Myoglobin (2021-2030) ($MN)
• Table 95 South America Cardiac Biomarkers Market Outlook, By Troponins (2021-2030) ($MN)
• Table 96 South America Cardiac Biomarkers Market Outlook, By Other Product Types (2021-2030) ($MN)
• Table 97 South America Cardiac Biomarkers Market Outlook, By Location of Testing (2021-2030) ($MN)
• Table 98 South America Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2021-2030) ($MN)
• Table 99 South America Cardiac Biomarkers Market Outlook, By Laboratory Testing (2021-2030) ($MN)
• Table 100 South America Cardiac Biomarkers Market Outlook, By Application (2021-2030) ($MN)
• Table 101 South America Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2021-2030) ($MN)
• Table 102 South America Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2021-2030) ($MN)
• Table 103 South America Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2021-2030) ($MN)
• Table 104 South America Cardiac Biomarkers Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 105 South America Cardiac Biomarkers Market Outlook, By End User (2021-2030) ($MN)
• Table 106 South America Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 107 South America Cardiac Biomarkers Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 108 South America Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
• Table 109 South America Cardiac Biomarkers Market Outlook, By Research Institutions (2021-2030) ($MN)
• Table 110 South America Cardiac Biomarkers Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 111 Middle East & Africa Cardiac Biomarkers Market Outlook, By Country (2021-2030) ($MN)
• Table 112 Middle East & Africa Cardiac Biomarkers Market Outlook, By Product Type (2021-2030) ($MN)
• Table 113 Middle East & Africa Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2021-2030) ($MN)
• Table 114 Middle East & Africa Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2021-2030) ($MN)
• Table 115 Middle East & Africa Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2021-2030) ($MN)
• Table 116 Middle East & Africa Cardiac Biomarkers Market Outlook, By Myoglobin (2021-2030) ($MN)
• Table 117 Middle East & Africa Cardiac Biomarkers Market Outlook, By Troponins (2021-2030) ($MN)
• Table 118 Middle East & Africa Cardiac Biomarkers Market Outlook, By Other Product Types (2021-2030) ($MN)
• Table 119 Middle East & Africa Cardiac Biomarkers Market Outlook, By Location of Testing (2021-2030) ($MN)
• Table 120 Middle East & Africa Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2021-2030) ($MN)
• Table 121 Middle East & Africa Cardiac Biomarkers Market Outlook, By Laboratory Testing (2021-2030) ($MN)
• Table 122 Middle East & Africa Cardiac Biomarkers Market Outlook, By Application (2021-2030) ($MN)
• Table 123 Middle East & Africa Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2021-2030) ($MN)
• Table 124 Middle East & Africa Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2021-2030) ($MN)
• Table 125 Middle East & Africa Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2021-2030) ($MN)
• Table 126 Middle East & Africa Cardiac Biomarkers Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 127 Middle East & Africa Cardiac Biomarkers Market Outlook, By End User (2021-2030) ($MN)
• Table 128 Middle East & Africa Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 129 Middle East & Africa Cardiac Biomarkers Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 130 Middle East & Africa Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
• Table 131 Middle East & Africa Cardiac Biomarkers Market Outlook, By Research Institutions (2021-2030) ($MN)
• Table 132 Middle East & Africa Cardiac Biomarkers Market Outlook, By Other End Users (2021-2030) ($MN)